NEW YORK (GenomeWeb) – Cancer Genetics today announced it has signed a non-binding letter of intent to buy Gentris for up to $6.25 million.

The deal, which will be treated as an asset purchase, is made up of $3.25 million in cash and $1.5 million in Cancer Genetics stock. It also includes up to $1.5 million from Cancer Genetics in performance-based earn-outs. The acquisition is expected to close in the third quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.